Media headlines about EntreMed (NASDAQ:CASI) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. EntreMed earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.5232559179795 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- CASI Pharmaceuticals Provides Update On EVOMELA® (finance.yahoo.com)
- Investing with Harold Pinter (bullionvault.com)
- HC Wainwright Analysts Give EntreMed (CASI) a $7.00 Price Target (americanbankingnews.com)
- BidaskClub Upgrades EntreMed (CASI) to “Buy” (americanbankingnews.com)
- EntreMed (CASI) Rating Increased to Buy at ValuEngine (americanbankingnews.com)
Shares of NASDAQ:CASI traded down $0.25 on Thursday, hitting $6.15. The company had a trading volume of 1,635,529 shares, compared to its average volume of 410,528. The company has a market cap of $501.74, a P/E ratio of -34.17 and a beta of 0.90. EntreMed has a 1-year low of $0.91 and a 1-year high of $7.20.
Several research firms have commented on CASI. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of EntreMed in a report on Wednesday. BidaskClub upgraded shares of EntreMed from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine upgraded shares of EntreMed from a “hold” rating to a “buy” rating in a report on Monday.
In other EntreMed news, major shareholder China Growth Fund Idg-Accel II bought 3,086,418 shares of EntreMed stock in a transaction dated Wednesday, March 21st. The stock was bought at an average price of $3.19 per share, with a total value of $9,845,673.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wei-Wu He bought 3,086,419 shares of EntreMed stock in a transaction dated Monday, March 19th. The stock was acquired at an average cost of $3.24 per share, with a total value of $9,999,997.56. Following the transaction, the director now owns 847,527 shares of the company’s stock, valued at approximately $2,745,987.48. The disclosure for this purchase can be found here. Insiders own 24.52% of the company’s stock.
EntreMed Company Profile
CASI Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma.
Receive News & Ratings for EntreMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EntreMed and related companies with MarketBeat.com's FREE daily email newsletter.